Shots:
- Gilead will price its COVID-19 treatment at $390/ vial in the US and other developed countries- with a 5days treatment course of 6 vials costing $2340/ patient while the price for private insurance companies will be $520/ vial
- Pricing the remdesivir at low value ensures the broad and equitable access for the therapy during the pandemic. The company has signed an agreement with HHS where HHS and states will decide on hospital allocations of the therapy until the end of Sept’2020. After that- HHS will not handle the allocation
- In developing countries- Gilead collaborated with multiple generic makers to deliver remdesivir at low cost
Click here to read full press release/ article | Ref: Gilead | Image: Gilead
Related News: Gilead Collaborates with Generics Makers to Supply Remdesivir in 127 Countries
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
